Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction

PRECISION BIOSCIENCES INC

Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.
Cash, equivalents $108.5M at Dec 31, 2024; cash runway expected into H2 2026.
PBGENE-HBV Phase 1 low-dose cohort (N=3) dosed; well-tolerated with no grade ≥2 AE; 2 of 3 patients showed substantial HBsAg reduction.
Partner iECURE reported complete clinical response in first infant dosed for OTC deficiency; ECUR-506 generally well tolerated.
Appointed Cindy Atwell as Chief Development and Business Officer and Dr. Cassie Gorsuch as Chief Scientific Officer in Jan 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.